Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma

Jonathan C. Yau, Colin Germond, Stefan Gluck, Christine Cripps, Shailendra Verma, Bruce F. Burns, Terry M. Koski, Diane C. Lister, Glenwood D. Goss

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Elderly patients with intermediate- or high-grade non-Hodgkin's lymphoma have a worse outcome than those who are younger than 60 years. It has been shown that aggressive combination chemotherapy is poorly tolerated in older patients resulting in a subsequent decrease in dose intensity. A phase II trial was conducted with mitoxantrone, prednimustine, and vincristine (NSO) in this group of patients. NSO consists of mitoxantrone 12 mg/M2 intravenously on day one, vincristine 1.4 mg/M2 intravenously on day 1 (maximum dose of two mg), and prednimustine 100 mg/M2 orally once a day for four days. NSO was repeated every 21 days. Thirty-six patients Were able to be evaluated. There were 18 males and 18 females with the median age of 71 (range 60-85). NSO was well tolerated and nonhematological toxicities were uncommon. More than 80% of the patients received 90% or greater of the intended dose. The complete response rate was 60.6% and partial response was 21.8%. At 60 months the Kaplan-Meier estimate of progression-free survival was 47.9% (standard error 8.6%) and actual survival was 40.6% (standard error 8.8%). There were no differences in outcome between those with performance status (PS) of zero or one and those with PS > 1. NSO is well tolerated by elderly patients including those with PS > 1. These results compare favorably with other combinations in elderly patients with aggressive non-Hodgkin's lymphoma.

Original languageEnglish
Pages (from-to)156-160
Number of pages5
JournalAmerican Journal of Hematology
Volume59
Issue number2
DOIs
StatePublished - Oct 1 1998
Externally publishedYes

Fingerprint

Prednimustine
Mitoxantrone
Vincristine
Non-Hodgkin's Lymphoma
Kaplan-Meier Estimate
Combination Drug Therapy
Disease-Free Survival

Keywords

  • Elderly
  • Mitoxantrone
  • Non-Hodgkin's lymphoma
  • Prednimustine
  • Vincristine

ASJC Scopus subject areas

  • Hematology

Cite this

Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma. / Yau, Jonathan C.; Germond, Colin; Gluck, Stefan; Cripps, Christine; Verma, Shailendra; Burns, Bruce F.; Koski, Terry M.; Lister, Diane C.; Goss, Glenwood D.

In: American Journal of Hematology, Vol. 59, No. 2, 01.10.1998, p. 156-160.

Research output: Contribution to journalArticle

Yau, Jonathan C. ; Germond, Colin ; Gluck, Stefan ; Cripps, Christine ; Verma, Shailendra ; Burns, Bruce F. ; Koski, Terry M. ; Lister, Diane C. ; Goss, Glenwood D. / Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma. In: American Journal of Hematology. 1998 ; Vol. 59, No. 2. pp. 156-160.
@article{307f994fad0b49a785569824872df868,
title = "Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma",
abstract = "Elderly patients with intermediate- or high-grade non-Hodgkin's lymphoma have a worse outcome than those who are younger than 60 years. It has been shown that aggressive combination chemotherapy is poorly tolerated in older patients resulting in a subsequent decrease in dose intensity. A phase II trial was conducted with mitoxantrone, prednimustine, and vincristine (NSO) in this group of patients. NSO consists of mitoxantrone 12 mg/M2 intravenously on day one, vincristine 1.4 mg/M2 intravenously on day 1 (maximum dose of two mg), and prednimustine 100 mg/M2 orally once a day for four days. NSO was repeated every 21 days. Thirty-six patients Were able to be evaluated. There were 18 males and 18 females with the median age of 71 (range 60-85). NSO was well tolerated and nonhematological toxicities were uncommon. More than 80{\%} of the patients received 90{\%} or greater of the intended dose. The complete response rate was 60.6{\%} and partial response was 21.8{\%}. At 60 months the Kaplan-Meier estimate of progression-free survival was 47.9{\%} (standard error 8.6{\%}) and actual survival was 40.6{\%} (standard error 8.8{\%}). There were no differences in outcome between those with performance status (PS) of zero or one and those with PS > 1. NSO is well tolerated by elderly patients including those with PS > 1. These results compare favorably with other combinations in elderly patients with aggressive non-Hodgkin's lymphoma.",
keywords = "Elderly, Mitoxantrone, Non-Hodgkin's lymphoma, Prednimustine, Vincristine",
author = "Yau, {Jonathan C.} and Colin Germond and Stefan Gluck and Christine Cripps and Shailendra Verma and Burns, {Bruce F.} and Koski, {Terry M.} and Lister, {Diane C.} and Goss, {Glenwood D.}",
year = "1998",
month = "10",
day = "1",
doi = "10.1002/(SICI)1096-8652(199810)59:2<156::AID-AJH9>3.0.CO;2-X",
language = "English",
volume = "59",
pages = "156--160",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma

AU - Yau, Jonathan C.

AU - Germond, Colin

AU - Gluck, Stefan

AU - Cripps, Christine

AU - Verma, Shailendra

AU - Burns, Bruce F.

AU - Koski, Terry M.

AU - Lister, Diane C.

AU - Goss, Glenwood D.

PY - 1998/10/1

Y1 - 1998/10/1

N2 - Elderly patients with intermediate- or high-grade non-Hodgkin's lymphoma have a worse outcome than those who are younger than 60 years. It has been shown that aggressive combination chemotherapy is poorly tolerated in older patients resulting in a subsequent decrease in dose intensity. A phase II trial was conducted with mitoxantrone, prednimustine, and vincristine (NSO) in this group of patients. NSO consists of mitoxantrone 12 mg/M2 intravenously on day one, vincristine 1.4 mg/M2 intravenously on day 1 (maximum dose of two mg), and prednimustine 100 mg/M2 orally once a day for four days. NSO was repeated every 21 days. Thirty-six patients Were able to be evaluated. There were 18 males and 18 females with the median age of 71 (range 60-85). NSO was well tolerated and nonhematological toxicities were uncommon. More than 80% of the patients received 90% or greater of the intended dose. The complete response rate was 60.6% and partial response was 21.8%. At 60 months the Kaplan-Meier estimate of progression-free survival was 47.9% (standard error 8.6%) and actual survival was 40.6% (standard error 8.8%). There were no differences in outcome between those with performance status (PS) of zero or one and those with PS > 1. NSO is well tolerated by elderly patients including those with PS > 1. These results compare favorably with other combinations in elderly patients with aggressive non-Hodgkin's lymphoma.

AB - Elderly patients with intermediate- or high-grade non-Hodgkin's lymphoma have a worse outcome than those who are younger than 60 years. It has been shown that aggressive combination chemotherapy is poorly tolerated in older patients resulting in a subsequent decrease in dose intensity. A phase II trial was conducted with mitoxantrone, prednimustine, and vincristine (NSO) in this group of patients. NSO consists of mitoxantrone 12 mg/M2 intravenously on day one, vincristine 1.4 mg/M2 intravenously on day 1 (maximum dose of two mg), and prednimustine 100 mg/M2 orally once a day for four days. NSO was repeated every 21 days. Thirty-six patients Were able to be evaluated. There were 18 males and 18 females with the median age of 71 (range 60-85). NSO was well tolerated and nonhematological toxicities were uncommon. More than 80% of the patients received 90% or greater of the intended dose. The complete response rate was 60.6% and partial response was 21.8%. At 60 months the Kaplan-Meier estimate of progression-free survival was 47.9% (standard error 8.6%) and actual survival was 40.6% (standard error 8.8%). There were no differences in outcome between those with performance status (PS) of zero or one and those with PS > 1. NSO is well tolerated by elderly patients including those with PS > 1. These results compare favorably with other combinations in elderly patients with aggressive non-Hodgkin's lymphoma.

KW - Elderly

KW - Mitoxantrone

KW - Non-Hodgkin's lymphoma

KW - Prednimustine

KW - Vincristine

UR - http://www.scopus.com/inward/record.url?scp=0031712419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031712419&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8652(199810)59:2<156::AID-AJH9>3.0.CO;2-X

DO - 10.1002/(SICI)1096-8652(199810)59:2<156::AID-AJH9>3.0.CO;2-X

M3 - Article

C2 - 9766801

AN - SCOPUS:0031712419

VL - 59

SP - 156

EP - 160

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -